Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Savara Inc (NASDAQ:SVRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $9.86.

A number of research firms recently commented on SVRA. Evercore ISI reaffirmed an "in-line" rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Wells Fargo & Company initiated coverage on Savara in a research note on Friday, December 20th. They set an "overweight" rating and a $8.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Finally, HC Wainwright decreased their price target on Savara from $10.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th.

Savara Stock Performance

Shares of SVRA stock remained flat at $2.69 during mid-day trading on Thursday. The stock had a trading volume of 692,862 shares, compared to its average volume of 599,084. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm has a market capitalization of $461.66 million, a P/E ratio of -6.26 and a beta of 0.63. Savara has a twelve month low of $2.59 and a twelve month high of $5.70. The firm's 50-day moving average is $2.93 and its 200-day moving average is $3.55.

Insider Activity

In other news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares of the company's stock, valued at $5,085,414.49. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 5.13% of the company's stock.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP raised its holdings in shares of Savara by 24.7% during the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company's stock valued at $34,302,000 after buying an additional 1,600,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock valued at $11,564,000 after buying an additional 264,825 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company's stock valued at $3,865,000 after buying an additional 642,259 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Savara by 54.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company's stock valued at $2,928,000 after buying an additional 242,249 shares during the period. Finally, Barclays PLC raised its holdings in shares of Savara by 217.5% during the 3rd quarter. Barclays PLC now owns 231,005 shares of the company's stock valued at $979,000 after buying an additional 158,244 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.